{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:42:18Z","timestamp":1792698138774,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2024\/53\/B\/NZ2\/00225"],"award-info":[{"award-number":["2024\/53\/B\/NZ2\/00225"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lab Anim Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite intensive studies on developing therapies for Alzheimer\u2019s disease (AD), there is still a need to improve the treatment efficacy. Results of recent studies indicated that genistein (4\u2032,5,7-trihydroxyisoflavone) was effective in an autophagy stimulation-dependent improving of cognitive deficits and reducing levels of amyloid-beta and hyperphosphorylated tau protein in brains, when employing a streptozotocin-induced rat model of the sporadic form of AD. Despite those encouraging results, the above-mentioned model has its limitations, mainly related to the rapid and inducible character of the symptoms caused by streptozotocin, induction of other effects (like diabetes) by this toxin, and the requirement for invasive administration of this compound to the brain, in contrast to naturally occurring AD. Thus, in this study, we hypothesized that genistein might be effective in reducing symptoms of AD in well-defined genetic models of this disease and tested the efficacy of this compound.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three genetic models of AD were employed, including mouse lines 5xFAD, THY-Tau22, and 3xTg-AD. Orally administered genistein (at the dose of 150\u00a0mg\/kg\/day) considerably alleviated cognitive deficits (in spatial memory, learning, and long-term memory) of AD animals as estimated using the Morris water maze and the novel object recognition tests. Moreover, significantly reduced levels of amyloid-beta and hyperphosphorylated tau protein in plasma and brains were detected in genistein-treated AD animals relative to those treated with water.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We conclude that genistein revealed significant efficacy in ameliorating symptoms occurring in murine genetic models of AD. Thus, further studies towards the development of a genistein-based treatment for this disease are substantiated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42826-026-00302-9","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:51:37Z","timestamp":1792651897000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The use of three murine genetic models of Alzheimer\u2019s disease reveals efficacy of 4\u2032,5,7-trihydroxyisoflavone in alleviating cognitive deficits and reducing levels of amyloid-beta and hyperphosphorylated tau protein"],"prefix":"10.1186","volume":"42","author":[{"given":"Lidia","family":"Gaffke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneta","family":"Szulc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Podlacha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"My\u015bli\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Pierzynowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4042-7466","authenticated-orcid":false,"given":"Grzegorz","family":"W\u0119grzyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"302_CR1","doi-asserted-by":"publisher","first-page":"543","DOI":"10.4103\/1673-5374.320970","volume":"17","author":"Y Ju","year":"2022","unstructured":"Ju Y, Tam KY. Pathological mechanisms and therapeutic strategies for Alzheimer\u2019s disease. Neural Regen Res. 2022;17:543\u20139.","journal-title":"Neural Regen Res"},{"key":"302_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41582-023-00789-z","volume":"19","author":"C Reitz","year":"2023","unstructured":"Reitz C, Pericak-Vance MA, Foroud T, Mayeux R. A global view of the genetic basis of Alzheimer disease. Nat Rev Neurol. 2023;19:261\u201377.","journal-title":"Nat Rev Neurol"},{"key":"302_CR3","first-page":"e12155","volume":"13","author":"J Hoogmartens","year":"2021","unstructured":"Hoogmartens J, Cacace R, Van Broeckhoven C. Insight into the genetic etiology of Alzheimer\u2019s disease: A comprehensive review of the role of rare variants. Alzheimers Dement. 2021;13:e12155.","journal-title":"Alzheimers Dement"},{"key":"302_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s43556-026-00443-2","volume":"7","author":"JQ Feng","year":"2026","unstructured":"Feng JQ, Yang LL, Luo YX, Yao XQ. Alzheimer\u2019s disease: from molecular pathways to therapies. Mol Biomed. 2026;7:43.","journal-title":"Mol Biomed"},{"key":"302_CR5","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41582-021-00520-w","volume":"17","author":"H Hampel","year":"2021","unstructured":"Hampel H, Cummings J, Blennow K, Gao P, Jack CR Jr, Vergallo A. Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nat Rev Neurol. 2021;17:580\u20139.","journal-title":"Nat Rev Neurol"},{"key":"302_CR6","first-page":"5380346","volume":"2020","author":"AE Oxford","year":"2020","unstructured":"Oxford AE, Stewart ES, Rohn TT. Clinical trials in Alzheimer\u2019s disease: A hurdle in the path of remedy. Int J Alzheimers Dis. 2020;2020:5380346.","journal-title":"Int J Alzheimers Dis"},{"key":"302_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12929-023-00976-6","volume":"30","author":"LK Huang","year":"2023","unstructured":"Huang LK, Kuan YC, Lin HW, Hu CJ. Clinical trials of new drugs for Alzheimer disease: a 2020\u20132023 update. J Biomed Sci. 2023;30:83.","journal-title":"J Biomed Sci"},{"key":"302_CR8","doi-asserted-by":"publisher","first-page":"240035","DOI":"10.1098\/rsob.240035","volume":"14","author":"M Gyimesi","year":"2024","unstructured":"Gyimesi M, Okolicsanyi RK, Haupt LM. Beyond amyloid and tau: rethinking Alzheimer\u2019s disease through less explored avenues. Open Biol. 2024;14:240035.","journal-title":"Open Biol"},{"key":"302_CR9","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.3390\/jcm13113098","volume":"13","author":"G Tondo","year":"2024","unstructured":"Tondo G, De Marchi F, Bonardi F, Menegon F, Verrini G, Aprile D, et al. Novel therapeutic strategies in Alzheimer\u2019s disease: pitfalls and challenges of anti-amyloid therapies and beyond. J Clin Med. 2024;13:3098.","journal-title":"J Clin Med"},{"key":"302_CR10","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s11011-018-0214-6","volume":"33","author":"K Pierzynowska","year":"2018","unstructured":"Pierzynowska K, Gaffke L, Cyske Z, Puchalski M, Rintz E, Bartkowski M, et al. Autophagy stimulation as a promising approach in treatment of neurodegenerative diseases. Metab Brain Dis. 2018;33:989\u20131008.","journal-title":"Metab Brain Dis"},{"key":"302_CR11","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/1440-1681.13500","volume":"48","author":"A Ajoolabady","year":"2021","unstructured":"Ajoolabady A, Aslkhodapasandhokmabad H, Henninger N, Demillard LJ, Nikanfar M, Nourazarian A, et al. Targeting autophagy in neurodegenerative diseases: From molecular mechanisms to clinical therapeutics. Clin Exp Pharmacol Physiol. 2021;48:943\u201353.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"302_CR12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/aps.2013.5","volume":"34","author":"YP Yang","year":"2013","unstructured":"Yang YP, Hu LF, Zheng HF, Mao CJ, Hu WD, Xiong KP, et al. Application and interpretation of current autophagy inhibitors and activators. Acta Pharmacol Sin. 2013;34:625\u201335.","journal-title":"Acta Pharmacol Sin"},{"key":"302_CR13","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.neuropharm.2019.01.030","volume":"148","author":"K Pierzynowska","year":"2019","unstructured":"Pierzynowska K, Podlacha M, Gaffke L, Majkutewicz I, Mantej J, W\u0119grzyn A, et al. Autophagy-dependent mechanism of genistein-mediated elimination of behavioral and biochemical defects in the rat model of sporadic Alzheimer\u2019s disease. Neuropharmacology. 2019;148:332\u201346.","journal-title":"Neuropharmacology"},{"key":"302_CR14","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1080\/15548627.2023.2286116","volume":"20","author":"K Pierzynowska","year":"2024","unstructured":"Pierzynowska K, Podlacha M, Gaffke L, Rintz E, Wi\u015bniewska K, Cyske Z, et al. Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation. Autophagy. 2024;20:1159\u201382.","journal-title":"Autophagy"},{"key":"302_CR15","doi-asserted-by":"publisher","first-page":"3268136","DOI":"10.1155\/2021\/3268136","volume":"2021","author":"J Sharifi-Rad","year":"2021","unstructured":"Sharifi-Rad J, Quispe C, Imran M, Rauf A, Nadeem M, Gondal TA, et al. Genistein: an integrative overview of its mode of action, pharmacological properties, and health benefits. Oxid Med Cell Longev. 2021;2021:3268136.","journal-title":"Oxid Med Cell Longev"},{"key":"302_CR16","first-page":"397","volume-title":"Bentham Briefs in Biomedicine and Pharmacotherapy","author":"E Rintz","year":"2021","unstructured":"Rintz E, Gaffke L, Pierzynowska K, Podlacha M, Mantej J, Bednarek M, et al. Genistein \u2013 a natural antioxidant and its use in treatment of various diseases. In: Lewandrowski K-U, editor. Bentham Briefs in Biomedicine and Pharmacotherapy. Sharjah (UAE): Bentham Science; 2021. pp. 397\u2013420."},{"key":"302_CR17","doi-asserted-by":"publisher","first-page":"115130","DOI":"10.1016\/j.taap.2020.115130","volume":"402","author":"TL Guo","year":"2021","unstructured":"Guo TL, Chen Y, Xu HS, McDonough CM, Huang G. Gut microbiome in neuroendocrine and neuroimmune interactions: The case of genistein. Toxicol Appl Pharmacol. 2021;402:115130.","journal-title":"Toxicol Appl Pharmacol"},{"key":"302_CR18","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s00394-020-02403-0","volume":"60","author":"R Yang","year":"2021","unstructured":"Yang R, Jia Q, Mehmood S, Ma S, Liu X. Genistein ameliorates inflammation and insulin resistance through mediation of gut microbiota composition in type 2 diabetic mice. Eur J Nutr. 2021;60:2155\u201368.","journal-title":"Eur J Nutr"},{"key":"302_CR19","doi-asserted-by":"publisher","first-page":"118627","DOI":"10.1016\/j.lfs.2020.118627","volume":"264","author":"P Kesika","year":"2021","unstructured":"Kesika P, Suganthy N, Sivamaruthi BS, Chaiyasut C. Role of gut-brain axis, gut microbial composition, and probiotic intervention in Alzheimer\u2019s disease. Life Sci. 2021;264:118627.","journal-title":"Life Sci"},{"key":"302_CR20","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3390\/biom11050678","volume":"11","author":"VK Sharma","year":"2021","unstructured":"Sharma VK, Singh TG, Garg N, Dhiman S, Gupta S, Rahman MH, et al. Dysbiosis and Alzheimer\u2019s disease: A role for chronic stress? Biomolecules. 2021;11:678.","journal-title":"Biomolecules"},{"key":"302_CR21","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s00702-025-02891-6","volume":"132","author":"E Gr\u00fcnblatt","year":"2025","unstructured":"Gr\u00fcnblatt E, Yde Ohki CM, Schmitt-B\u00f6hrer GA, Riederer P, Walitza S. Exploring the interplay of glucose metabolism, insulin resistance, and neurodegenerative pathologies: insights from streptozotocin and hypoglycaemic in vitro models. J Neural Transm. 2025;132:1479\u201391.","journal-title":"J Neural Transm"},{"key":"302_CR22","doi-asserted-by":"publisher","first-page":"713726","DOI":"10.3389\/fnagi.2021.713726","volume":"13","author":"AL Oblak","year":"2021","unstructured":"Oblak AL, Lin PB, Kotredes KP, Pandey RS, Garceau D, Williams HM, et al. Comprehensive evaluation of the 5XFAD mouse model for preclinical testing applications: A MODEL-AD study. Front Aging Neurosci. 2021;13:713726.","journal-title":"Front Aging Neurosci"},{"key":"302_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.bbr.2012.12.008","volume":"242","author":"A Van der Jeugd","year":"2013","unstructured":"Van der Jeugd A, Blum D, Raison S, Eddarkaoui S, Bu\u00e9e L, D\u2019Hooge R. Observations in THY-Tau22 mice that resemble behavioral and psychological signs and symptoms of dementia. Behav Brain Res. 2013;242:34\u20139.","journal-title":"Behav Brain Res"},{"key":"302_CR24","doi-asserted-by":"publisher","first-page":"147437","DOI":"10.1016\/j.brainres.2021.147437","volume":"1762","author":"T Pairojana","year":"2021","unstructured":"Pairojana T, Phasuk S, Suresh P, Huang SP, Pakaprot N, Chompoopong S, et al. Age and gender differences for the behavioral phenotypes of 3xTg Alzheimer\u2019s disease mice. Brain Res. 2021;1762:147437.","journal-title":"Brain Res"},{"issue":"10","key":"302_CR25","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.3390\/biom14101294","volume":"14","author":"EW Westi","year":"2024","unstructured":"Westi EW, Molhemi S, Hansen CT, Skoven CS, Knopper RW, Ahmad DA, et al. Comprehensive analysis of the 5xFAD mouse model of Alzheimer\u2019s disease using dMRI, immunohistochemistry, and neuronal and glial functional metabolic mapping. Biomolecules. 2024;14(10):1294.","journal-title":"Biomolecules"},{"key":"302_CR26","first-page":"CD016297","volume":"4","author":"F Nonino","year":"2026","unstructured":"Nonino F, Minozzi S, Sambati L, Del Giovane C, Baldin E, Bassi MC, et al. Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer\u2019s disease. Cochrane Database Syst Rev. 2026;4:CD016297.","journal-title":"Cochrane Database Syst Rev"},{"key":"302_CR27","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.4103\/NRR.NRR-D-24-00713","volume":"20","author":"K Pierzynowska","year":"2025","unstructured":"Pierzynowska K, Karaszewski B, W\u0119grzyn G. Genistein: a possible solution for the treatment of Alzheimer\u2019s disease. Neural Regen Res. 2025;20:2903\u201305.","journal-title":"Neural Regen Res"},{"key":"302_CR28","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ymgme.2013.06.012","volume":"109","author":"KH Kim","year":"2013","unstructured":"Kim KH, Dodsworth C, Paras A, Burton BK. High dose genistein aglycone therapy is safe in patients with mucopolysaccharidoses involving the central nervous system. Mol Genet Metab. 2013;109:382\u20135.","journal-title":"Mol Genet Metab"},{"key":"302_CR29","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/j.neuron.2021.03.026","volume":"109","author":"E Lester","year":"2021","unstructured":"Lester E, Ooi FK, Bakkar N, Ayers J, Woerman AL, Wheeler J, et al. Tau aggregates are RNA-protein assemblies that mislocalize multiple nuclear speckle components. Neuron. 2021;109:1675\u2013e919.","journal-title":"Neuron"},{"key":"302_CR30","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.ijbiomac.2021.03.107","volume":"181","author":"W Smeralda","year":"2021","unstructured":"Smeralda W, Since M, Cardin J, Corvaisier S, Lecomte S, Cullin C, et al. \u03b2-Amyloid peptide interactions with biomimetic membranes: A multiparametric characterization. Int J Biol Macromol. 2021;181:769\u201377.","journal-title":"Int J Biol Macromol"},{"key":"302_CR31","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1021\/acschemneuro.0c00688","volume":"12","author":"S Banerjee","year":"2021","unstructured":"Banerjee S, Hashemi M, Zagorski K, Lyubchenko YL. Cholesterol in membranes facilitates aggregation of amyloid beta protein at physiologically relevant concentrations. ACS Chem Neurosci. 2021;12:506\u201316.","journal-title":"ACS Chem Neurosci"},{"key":"302_CR32","doi-asserted-by":"publisher","first-page":"5559","DOI":"10.1021\/acs.jpcb.1c02797","volume":"125","author":"KW Hu","year":"2021","unstructured":"Hu KW, Fan HF, Lin HC, Huang JW, Chen YC, Shen CL, et al. Exploring the impact of glyoxal glycation on beta-amyloid peptide (Abeta) aggregation in Alzheimer\u2019s disease. J Phys Chem B. 2021;125:5559\u201371.","journal-title":"J Phys Chem B"},{"key":"302_CR33","unstructured":"Le W, editor. Autophagy: Biology and Diseases. Springer, Singapore. 2020. ISBN: 978-981-15-4271-8."},{"key":"302_CR34","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3233\/JAD-151020","volume":"51","author":"V Bonet-Costa","year":"2016","unstructured":"Bonet-Costa V, Herranz-P\u00e9rez V, Blanco-Gand\u00eda M, Mas-Bargues C, Ingl\u00e9s M, Garcia-Tarraga P, et al. Clearing amyloid-\u03b2 through PPAR\u03b3\/ApoE activation by genistein is a treatment of experimental Alzheimer\u2019s disease. J Alzheimers Dis. 2016;51:701\u201311.","journal-title":"J Alzheimers Dis"},{"key":"302_CR35","doi-asserted-by":"publisher","first-page":"692","DOI":"10.3390\/nu8110692","volume":"8","author":"YJ Park","year":"2016","unstructured":"Park YJ, Ko JW, Jeon S, Kwon YH. Protective effect of genistein against neuronal degeneration in ApoE-\/- mice fed a high-fat diet. Nutrients. 2016;8:692.","journal-title":"Nutrients"},{"key":"302_CR36","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.4103\/1673-5374.187056","volume":"11","author":"Y Wang","year":"2016","unstructured":"Wang Y, Cai B, Shao J, Wang TT, Cai RZ, Ma CJ, et al. Genistein suppresses the mitochondrial apoptotic pathway in hippocampal neurons in rats with Alzheimer\u2019s disease. Neural Regen Res. 2016;11:1153\u20138.","journal-title":"Neural Regen Res"},{"key":"302_CR37","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.nut.2013.06.006","volume":"30","author":"X Zhou","year":"2014","unstructured":"Zhou X, Yuan L, Zhao X, Hou C, Ma W, Yu H, et al. Genistein antagonizes inflammatory damage induced by \u03b2-amyloid peptide in microglia through TLR4 and NF-\u03baB. Nutrition. 2014;30:90\u20135.","journal-title":"Nutrition"},{"key":"302_CR38","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.nlm.2010.12.001","volume":"95","author":"M Bagheri","year":"2011","unstructured":"Bagheri M, Joghataei MT, Mohseni S, Roghani M. Genistein ameliorates learning and memory deficits in amyloid \u03b2(1\u201340) rat model of Alzheimer\u2019s disease. Neurobiol Learn Mem. 2011;95:270\u20136.","journal-title":"Neurobiol Learn Mem"},{"key":"302_CR39","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1007\/s12031-021-01829-3","volume":"71","author":"P Nagu","year":"2021","unstructured":"Nagu P, Parashar A, Behl T, Mehta V. Gut microbiota composition and epigenetic molecular changes connected to the pathogenesis of Alzheimer\u2019s disease. J Mol Neurosci. 2021;71:1436\u201355.","journal-title":"J Mol Neurosci"},{"key":"302_CR40","doi-asserted-by":"publisher","first-page":"105135","DOI":"10.1016\/j.phrs.2020.105135","volume":"161","author":"P Dey","year":"2020","unstructured":"Dey P. Targeting gut barrier dysfunction with phytotherapies: Effective strategy against chronic diseases. Pharmacol Res. 2020;161:105135.","journal-title":"Pharmacol Res"},{"key":"302_CR41","doi-asserted-by":"publisher","first-page":"710683","DOI":"10.3389\/fnagi.2021.710683","volume":"13","author":"AD Snow","year":"2021","unstructured":"Snow AD, Cummings JA, Lake T. The unifying hypothesis of Alzheimer\u2019s disease: Heparan sulfate proteoglycans\/glycosaminoglycans are key as first hypothesized over 30 years ago. Front Aging Neurosci. 2021;13:710683.","journal-title":"Front Aging Neurosci"},{"key":"302_CR42","first-page":"177","volume":"53","author":"P Tanjak","year":"2018","unstructured":"Tanjak P, Thiantanawat A, Watcharasit P, Satayavivad J. Genistein reduces the activation of AKT and EGFR, and the production of IL6 in cholangiocarcinoma cells involving estrogen and estrogen receptors. Int J Oncol. 2018;53:177\u201388.","journal-title":"Int J Oncol"},{"key":"302_CR43","doi-asserted-by":"publisher","first-page":"9378","DOI":"10.1038\/srep09378","volume":"5","author":"M Moskot","year":"2015","unstructured":"Moskot M, Jak\u00f3bkiewicz-Banecka J, Kloska A, Smoli\u0144ska E, Mozolewski P, Malinowska M, et al. Modulation of expression of genes involved in glycosaminoglycan metabolism and lysosome biogenesis by flavonoids. Sci Rep. 2015;5:9378.","journal-title":"Sci Rep"},{"key":"302_CR44","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1423-0127-16-26","volume":"16","author":"J Jak\u00f3bkiewicz-Banecka","year":"2009","unstructured":"Jak\u00f3bkiewicz-Banecka J, Piotrowska E, Narajczyk M, Bara\u0144ska S, Wegrzyn G. Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway. J Biomed Sci. 2009;16:26.","journal-title":"J Biomed Sci"},{"key":"302_CR45","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1080\/1028415X.2026.2634117","volume":"29","author":"K Pierzynowska","year":"2026","unstructured":"Pierzynowska K, Gaffke L, Cyske Z, Jerzemowska G, W\u0119grzyn G, Podlacha M. Potential effects of genistein in preventing progressive loss of cognitive functions in wild-type mice. Nutr Neurosci. 2026;29:1153\u201373.","journal-title":"Nutr Neurosci"},{"key":"302_CR46","doi-asserted-by":"publisher","first-page":"102918","DOI":"10.1016\/j.arr.2025.102918","volume":"113","author":"K Le\u00f3n-Arcia","year":"2026","unstructured":"Le\u00f3n-Arcia K, Andrade-Guerrero J, Mart\u00ednez-Orozco H, Villegas-Rojas MM, P\u00e9rez-Segura I, Ram\u00edrez IL, et al. First unified time-course of Alzheimer\u2019s-like pathology in the intracerebroventricular streptozotocin-rat model: A systematic review. Ageing Res Rev. 2026;113:102918.","journal-title":"Ageing Res Rev"},{"key":"302_CR47","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s11011-020-00617-z","volume":"35","author":"K Pierzynowska","year":"2020","unstructured":"Pierzynowska K, Kami\u0144ska T, W\u0119grzyn G. One drug to treat many diseases: unlocking the economic trap of rare diseases. Metab Brain Dis. 2020;35:1237\u201340.","journal-title":"Metab Brain Dis"}],"container-title":["Laboratory Animal Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42826-026-00302-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42826-026-00302-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42826-026-00302-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:01:52Z","timestamp":1792695712000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42826-026-00302-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["302"],"URL":"https:\/\/doi.org\/10.1186\/s42826-026-00302-9","relation":{},"ISSN":["2233-7660"],"issn-type":[{"value":"2233-7660","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"6 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Experiments with the use of mice, reported in this work, were approved by the Local Ethics Committee for the Care and Use of Laboratory Animals in Bydgoszcz, Poland (resolution no. 41\/2022).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"41"}}